Introduction: Disclaim of the Chagas disease case in Blood Center is based on the immunofluorescence and enzyme-linked immunosorbent antibody assays.
Introduction
Chagas disease used to be limited to rural regions of the American Continent infested with triatomine (Reduviidae:Triatomine) bug transmitter of Trypanosoma cruzi infection. 1 The epidemiological profile changed as a consequence of social and economic a cause that underlies the human exodus mostly of the South and Central America to the Northern Hemisphere. Now present in five Continents the disease poses a growing burden to the public health systems. [2] [3] [4] [5] [6] [7] The infection can be transmitted congenitally by a Chagas' mother to the offspring, by blood transfusion, by organ transplantation, by the ingestion of contaminated food, and by accident in the research laboratory and health facilities. In addition, the T. cruzi can be transmitted sexually to naive females and males. [8] [9] [10] Acute Chagas disease with fever and malaise usually subsides on average of three months. The chronic infection can continue for life without clinical manifestation. However, the pathology manifests in one-third of those with Chagas heart disease ( Figure 1 ), mega colon and mega esophagus ( Figure 2 ).10 The acute infection is diagnosed by parasitological demonstration and by specific IgM antibody 15 days after parasite acquisition10. The chronic T. cruzi infection specific IgG antibody is showed by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA). The health facilities rely on trade mark kits of these assays to disclaim blood donors, and an automated chemiluminescent kit showing 97.6% specificity can be used for the diagnosis of Chagas disease in health facilities. 8 However, the varying sensitivity and specificity of methods to diagnose the Trypanosoma cruzi infection has raised concerns regarding the safety and accuracy of blood donor disclaimers. In this regard, a PCR technology that discloses 10 femtograms of T. cruzi DNA, which is 1/24 of the total diploid parasite DNA, is recommended11. The specificity of nuclear DNA-PCR, Southern blotting with radio labeled specific 188-nucleotides telomere sequence, cloning and sequencing of amplicons (nDNA-PCR) was noted in 21 cases of acute Chagas disease ( Figure 3 ) with parasitological demonstration. 12, 13 The reliability of the methods was assessed in double-blind control experiments that included de-identified DNA samples from chronic In addition, a field study comprising 36 members of two families from São Felipe County, Bahia, Brazil, revealed nDNA-PCR positive in 61% (22/36) of cases, whereas ELISA and IF were positive in 22% (8/36) of individuals. Two independent investigations conducted in the family' studies in two ecosystems at different occasions confirmed the broad discrepancies among the ratios of positive antibody assays and those obtained by the nucleic acid test: the antibody tests were positive in 26.9% (39/145) subjects, whereas the Trypanosoma cruzi nuclear DNA-PCR was positive in 72.4% (105/145) of blood samples tested. 
Figure 3
The genotype of Trypanosoma cruzi isolates from acute Chagas disease shown by nucleic acids assay. A) nDNA-PCR 188-nt bands formed after Southern hybridization with the specific radio labeled probe. B) The T. cruzi bright-field image depicted the parasite trypomastigote visible with a primary IgG to the digoxigenin labeled probe after incubation with a secondary fluorescent antibody, and merge of previous images. C) The T. cruzi hybridization with the specific 188-nt digoxigenin-labeled probe, showing dark nucleus stained by an alkaline phosphatase-labeled monoclonal Ab to digoxigenin. Inserts show negative controls. Reprinted with permissions from the Author and the Publisher. 12 
